Subsidiary of Changchun High-Tech Industry (000661.SZ) approved for clinical trial application for trivalent influenza virus split vaccine (BK-01 adjuvant)

Changchun High-Tech Industry (000661.SZ) announced that its subsidiary Changchun Bcht Biotechnology has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its trivalent influenza split vaccine (BK-01 adjuvant), allowing it to conduct clinical trials for the prevention of epidemic influenza caused by various types of influenza viruses.